 |
Европейская академия
|
| В начало | Энциклопедия ЕАЕН | |
Энциклопедия Европейской академии естественных наук |
||
Yang Wei
Yang Wei, Senior Engineer, Class II professor-level, Director of Guangdong Provincial Key Laboratory of Non-Clinical Evaluation and Research of Drugs, director of Guangzhou Bay Area Biomedical Research Institute, director of National Key Laboratory of Eye Disease Prevention and Treatment (former State Key Laboratory of Ophthalmology), chief scientist of Guangdong Lewwin Pharmaceutical Research Institute Co., LTD. He is an expert of New Drug Evaluation in the Drug Evaluation Center of the State Drug Administration and a GLP expert in the Examination and Verification Center, and a leading talent in the field of national science and technology innovation and entrepreneurship (he has passed the final defense). A leading talent in Guangdong special support technology, Guangzhou Excellent Expert A Certificate, Pearl River Science and technology star. He is the deputy secretary general of the Chinese Society of Toxicology, and the deputy chairman and Secretary General of the Special Committee on Drug Toxicology and Safety Evaluation of the Chinese Society of Toxicology. Vice Chairman and Secretary General of Expert Committee on Toxicology of Traditional Chinese Medicine and Natural Drugs, and Vice Chairman and Secretary General of Professional Committee of Safety Pharmacology of Chinese Pharmacological Society, etc.
He has long been committed to the research of pharmacology and toxicology of innovative drugs as well as the research and transformation of new drugs, and is committed to building an international innovative drug evaluation and transformation research platform in line with international and domestic GLP standards, international AAALAC requirements, FDA standards and ICH requirements. He has created the first private institution in China and the first (currently the only one) research institution in South China with all ten GLP certification qualifications of NMPA drugs, which is fully recognized by the International AAALAC. The research data of the institute meet the reporting requirements of China and the United States. It is the first national-level specialized, special and new key small giant enterprise in China's GLP field, the first drug GLP certification institution to win the "Excellent Enterprise" award in the National Competition of China Innovation and Entrepreneurship Competition, and a high-end platform in the key technology field of China's top international drug non-clinical evaluation research.
As the project leader and the person in charge of pharmacology and toxicology research, he has participated in and presided over nearly 100 national, provincial and ministerial level and urban level science and technology research projects (presided over nearly 30 projects, 4 talent projects, 5 provincial and municipal science and technology achievement certificates, and 1 Guangzhou Science and Technology Progress Award). Including 18 national projects (973 and 863 projects each 1, new drug development major special 8 (as the head of pharmacology and toxicology research), 2 international cooperation projects (as the head of pharmacology and toxicology research), 2 national support plan). Among the 973 projects, he was the person in charge of the toxicity and compatibility reduction research projects of toxic Chinese medicines such as Tripterygium wilfordis and Kunming Mountain Begonia.
He led the formulation of one national standard, participated in the formulation of 16 national standards, applied for 33 patents, obtained the authorization of 19 national invention patents, published 6 monographs, and published more than 200 papers.
| Энциклопедия ЕАЕН |